Who are Clene Inc.'s main suppliers?

Clene Inc. (CLNN) key suppliers include: 4LIFE, NEW-YORK-UNIVERSITY, AE-CAPITAL-LIMITED, A-GLOBAL-CHORUS-FOUNDATION, GLENN-AND-SHELINA-WAY and 1 more. View the full supplier network at chainsifter.com/chain/CLNN.

Who are Clene Inc.'s major customers?

Clene Inc. (CLNN) key customers include: 4LIFE-RESEARCH-LLC, BTIG-LLC, CANACCORD-GENUITY-LLC, CHELSEA-WORLDWIDE-INC, CLENE-AUSTRALIA-PTY-LTD and 6 more. View the full customer network at chainsifter.com/chain/CLNN.

What sector is Clene Inc. in?

Clene Inc. (CLNN) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Clene Inc. Supplier List (CLNN): 6 Verified Suppliers

6Suppliers

11Customers

3Debt Items

1Related Chains

Source-Backed Evidence Depth

Clene Inc. (CLNN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

21Total relationships

5Distinct source URLs

10High confidence

0.756Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Clene Inc. Suppliers

Ticker	Name	Confidence	Evidence
4LIFE	4LIFE	92%	The Company has license and supply agreements with 4Life, through which it licenses and sells non-pharmaceutical products.
NEW-YORK-UNIVERSITY	NEW-YORK-UNIVERSITY	92%	Subaward, disbursement of funds will be paid to the Company based on the Company’s submission of invoices to NYU for reimbursement not more often than monthly.
AE-CAPITAL-LIMITED	AE-CAPITAL-LIMITED	90%	The Notes were issued on August 13, 2025. Pursuant to the Amendment, (i) the maturity date was extended to the earlier of (A) August 13, 2027 or (B) a change in control as defined in the Amendment
A-GLOBAL-CHORUS-FOUNDATION	A-GLOBAL-CHORUS-FOUNDATION	90%	The Notes were issued on August 13, 2025. Pursuant to the Amendment, (i) the maturity date was extended to the earlier of (A) August 13, 2027 or (B) a change in control as defined in the Amendment
GLENN-AND-SHELINA-WAY	GLENN-AND-SHELINA-WAY	90%	The Notes were issued on August 13, 2025. Pursuant to the Amendment, (i) the maturity date was extended to the earlier of (A) August 13, 2027 or (B) a change in control as defined in the Amendment
IGTA	Inception Growth Acquisition Limited	62%	Reciprocal relationship from IGTA graph: ing high returns for investors. In addition, we have a unique advantage as Mr. Felix Wong, our Chief Financial Officer, has track record in successfully compl…

Clene Inc. Customers

Ticker	Name	Confidence	Evidence
4LIFE-RESEARCH-LLC	4LIFE-RESEARCH-LLC	92%	dietary supplements are marketed and distributed through our wholly-owned subsidiary, dOrbital, Inc. or through an exclusive license with 4Life Research LLC
BTIG-LLC	BTIG-LLC	62%	of $3.3 million. Significant non-cash items included: (i) depreciation expense of $0.4 million related to laboratory and office equipment and leasehold improvements, (ii) non-cash lease expense of $0…
CANACCORD-GENUITY-LLC	CANACCORD-GENUITY-LLC	62%	marketable securities of $0.2 million, (x) non-cash interest expense on notes payable of $0.1 million due to amortization of debt discounts on notes payable, (xi) a change in fair value of our common…
CHELSEA-WORLDWIDE-INC	CHELSEA-WORLDWIDE-INC	62%	of novel clean-surfaced nanotechnology therapeutics. We have developed an electro-crystal-chemistry drug development platform that enables production of concentrated, stable, highly active, clean-sur…
CLENE-AUSTRALIA-PTY-LTD	CLENE-AUSTRALIA-PTY-LTD	62%	81 (78 )% * Not meaningful. The change in research and development expenses was primarily due to the following: (i) a decrease in expenses related to our lead drug candidate, CNM-Au8, primarily due t…
CLOSING-DATE-CHELSEA-WORLDWIDE-INC	CLOSING-DATE-CHELSEA-WORLDWIDE-INC	62%	of novel clean-surfaced nanotechnology therapeutics. We have developed an electro-crystal-chemistry drug development platform that enables production of concentrated, stable, highly active, clean-sur…
CREATIVE-WORLDWIDE-INC	CREATIVE-WORLDWIDE-INC	62%	of novel clean-surfaced nanotechnology therapeutics. We have developed an electro-crystal-chemistry drug development platform that enables production of concentrated, stable, highly active, clean-sur…
DELAWARE-CLENE-AUSTRALIA-PTY-LTD	DELAWARE-CLENE-AUSTRALIA-PTY-LTD	62%	of novel clean-surfaced nanotechnology therapeutics. We have developed an electro-crystal-chemistry drug development platform that enables production of concentrated, stable, highly active, clean-sur…
PLAN-THE-CLENE-INC	PLAN-THE-CLENE-INC	62%	David Lisonbee, who is also a stockholder and board member of a subsidiary of Clene. In accordance with the 2024 SSCP Note terms, we first used the proceeds to satisfy our obligations under a previou…
REVERSE-RECAPITALIZATION-CLENE-NANOMEDICINE-INC	REVERSE-RECAPITALIZATION-CLENE-NANOMEDICINE-INC	62%	tic activity for therapeutic use. Our clean-surfaced nanocrystals exhibit catalytic activities many-fold higher than other commercially available nanoparticles, produced using various techniques, tha…
STOCK-COMPENSATION-PLANS-THE-CLENE-NANOMEDICINE-	STOCK-COMPENSATION-PLANS-THE-CLENE-NANOMEDICINE-	62%	David Lisonbee, who is also a stockholder and board member of a subsidiary of Clene. In accordance with the 2024 SSCP Note terms, we first used the proceeds to satisfy our obligations under a previou…

Clene Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CLNN-DEBT-8685	Warrants outstanding: 10410247	90%	xbrl warrant detail from xbrl 2026-03-31.
CLNN-DEBT-8686	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2024-12-31.
CLNN-DEBT	Debt stack $23.5M	90%	Market cache reports total debt of $23.5M.

Clene Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Clene Inc..

Clene Inc. Ownership

Holder	Name	Confidence	Evidence
CLNN-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 29 tracked holders.

Clene Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
IGTA	Inception Growth Acquisition Limited	100.00	1	['supplier']

Clene Inc. Supply Chain